Product Description
Mechanisms of Action: CRTH2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Brazil | Chile | Colombia | Dominican Republic | Germany | Hungary | India | Ireland | Italy | New Zealand | Russia | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Hyperlipoproteinemias|Dyslipidemia|Hyperlipidemia|Type 2 Diabetes|Hypercholesterolemia|Myocardial Ischemia|Coronary Artery Disease|Atherosclerosis|Inflammation|Oxidative Stress
Phase 3: Dyslipidemia|Hypercholesterolemia|Type 2 Diabetes|Hyperlipoproteinemia Type V|Hyperlipoproteinemias|Hyperlipidemia|Lipidoses|Coronary Artery Disease|Coronary Disease|Hyperlipoproteinemia Type II|Myocardial Infarction|Peripheral Arterial Disease|Stroke|Intermittent Claudication|Myocardial Ischemia|Peripheral Vascular Diseases
Phase 2: Dyslipidemia|Asthma|Hypercholesterolemia|Rhinitis, Allergic, Seasonal|Flushing
Phase 1: Type 2 Diabetes|Dyslipidemia|Hyperlipidemia|Hypercholesterolemia|Hyperlipoproteinemia Type II|Rosacea
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NILACH | P4 |
Terminated |
Atherosclerosis |
2014-07-01 |
|
MK-0524A-119 | N/A |
Terminated |
Dyslipidemia|Hypercholesterolemia |
2013-05-01 |
|
MK-0524A-133 | P3 |
Terminated |
Hypercholesterolemia|Dyslipidemia |
2013-02-26 |
|
2010-019954-42 | P4 |
Terminated |
Unknown |
2013-01-18 |